Skip to main content

Table 3 Univariate and multivariate analyses of clinical features and biomarkers with patients’ overall survival (cohort P)

From: Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma

   Univariate analysis Multivariate analysis
HR(95 % CI) P value a HR(95 % CI) P valuea
wtERa high vs. low 0.455 (0.202–1.025) 0.058 0.519 (0.156–1.723) 0.284
ERa36 high vs. low 1.070 (0.501–2.282) 0.862 2.853 (0.843–9.654) 0.092
ERb high vs. low 1.121 (0.524–2.402) 0.768 1.151 (0.342–3.867) 0.820
Age >58 vs. ≤58 1.536 (0.698–3.380) 0.286 1.767 (0.503–6.205) 0.375
Gender Female vs. Male 0.314 (0.125–0.787) 0.013 0.186 (0.047–0.733) 0.016
AFP (ng/ml) >18 vs. ≤18 0.896 (0.415–1.935) 0.780 0.978 (0.327–2.925) 0.969
Tumor number Multiple vs. Single 4.660 (2.069–10.495) 0.000 2.065 (0.635–6.719) 0.228
Tumor size (cm) >5 vs. ≤5 3.528 (1.635–7.612) 0.001 4.679 (1.441–15.195) 0.010
Vascular invasion Yes vs. No 2.695 (1.165–6.231) 0.020 0.282 (0.058–1.361) 0.115
Intra-hepatic recurrence Yes vs. No 2.118 (0.967–4.640) 0.061 0.718 (0.192–2.689) 0.623
Extra-hepatic metastasis Yes vs. No 2.741 (1.216–6.181) 0.015 2.177 (0.714–6.638) 0.171
Neo-adjuvant treatments Yes vs. No 3.851 (1.121–13.230) 0.032 2.132 (0.341–13.318) 0.418
Adjuvant treatments Yes vs. No 4.522 (1.393–14.687) 0.012 11.204 (2.231–56.266) 0.003
Liver cirrhosis Yes vs. No 3.377 (1.258–9.062) 0.016 5.202 (1.324–20.435) 0.018
HBsAg + vs. - 0.542 (0.241–1.215) 0.137 0.596 (0.153–2.317) 0.455
  1. Abbreviation: HR hazard ratio, OS overall survival, CI confidence interval
  2. Significant data are highlighted in bold. a Correlation is significant at the 0.01 a level (2-tailed)